T-Cypher Bio Announces Formation of Scientific Advisory Board padovanews.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from padovanews.it Daily Mail and Mail on Sunday newspapers.
Published: Apr 21, 2021
- Backed by leading healthcare investors including SV Health Investors -
Cambridge, UK, 20 April 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced its launch with $11 million seed financing from healthcare investors SV Health Investors and Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”).
The Company’s mission is to develop new medicines for patients by targeting activated fibroblast populations and their role in influencing immune effector cells in disease. Powerful new technologies enable diseased tissues to be analyzed at a single-cell level, and this work has uncovered discrete fibroblast cell sub-populations shared across diseases, acting as “immune sentinels” in perpetuating, and progressing disease. Mestag is building a pipeline of first in class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncolog
Historic Fife postcards by 19th century artist Reginald Phillimore celebrated by retired consultant rheumatologist
Sign up for our daily newsletter of the top stories in Courier country
Thank you for signing up to The Courier daily newsletter
Something went wrong - please try again later. Sign Up
Michael Alexander speaks to retired consultant rheumatologist Jan Bondeson about his fascination with the works of a 19th century postcard artist who created various images of landmarks in the East Neuk of Fife.
When Swedish-born physician Jan Bondeson retired as a lecturer and consultant rheumatologist at the Cardiff University School of Medicine a few years ago, it gave him more time to indulge in his hobby of collecting books, art and postcards.
Vaccine Responses in Older Adults Boosted by Drug That Helps Immune Cells Self-Clean
December 16, 2020
One needs to look no further than the COVID-19 pandemic to highlight the point that older adults are in the high-risk category for infectious diseases. With vaccines starting to be rolled out in the United States, so too is hope for the protection of this vulnerable group. While most vaccines are less efficacious in older adults, little is known about the molecular mechanisms that underpin this.
A new study shows that autophagy, a process critical for the maintenance of immune memory in mice, is specifically induced in vaccine-induced antigen-specific CD8+ T cells in healthy human volunteers. In addition, a drug that boosts the removal of cellular debris in immune cells, spermidine, may increase the protective effects of vaccines in older adults. The results may lead to new approaches to protect older individuals from viruses such as the one causing the current COVID-19 pandemic
E-Mail
A drug that boosts the removal of cellular debris in immune cells may increase the protective effects of vaccines in older adults, a study published today in
eLife shows.
The results may lead to new approaches to protect older individuals from viruses such as the one causing the current COVID-19 pandemic and influenza. Older adults are at high risk of being severely affected by infectious diseases, but unfortunately most vaccines in this age group are less efficient than in younger adults, explains lead author Ghada Alsaleh, a postdoctoral researcher at the Kennedy Institute of Rheumatology, University of Oxford, UK.